- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Serina Therapeutics to Present Novel Lipid Nanoparticle Technology at Summit
Company's POZ Platform aims to improve safety and versatility of LNP-based therapeutics
Apr. 7, 2026 at 10:24am
Got story updates? Submit your updates here. ›
Serina Therapeutics' innovative lipid nanoparticle platform aims to unlock new frontiers in oligonucleotide drug delivery.Huntsville TodaySerina Therapeutics, a clinical-stage biotech company, announced that its Chief Development Officer, Randall Moreadith, MD, PhD, will present data on the company's proprietary POZ Platform technology at the 5th LNP Formulation & Process Development Summit in Boston. The presentation will highlight how Serina's novel lipid nanoparticles, built entirely on the POZ Platform, can overcome the immunogenicity issues associated with the standard PEG-lipids used in most LNP formulations. Serina will also showcase its work on developing new ionizable lipid replacements to address safety concerns with current LNP components.
Why it matters
Lipid nanoparticle (LNP) technology is a critical delivery system for a variety of oligonucleotide-based therapeutics, including mRNA vaccines. However, the standard PEG-lipids and ionizable lipids used in LNP formulations have been linked to safety issues like immune responses and toxicity. Serina's POZ Platform aims to provide a safer and more versatile LNP alternative that could unlock the full potential of this important drug delivery technology.
The details
Serina's POZ-based lipid nanoparticles have demonstrated the ability to avoid the antibody response seen with standard PEG-lipids in preclinical studies. The company is also advancing novel ionizable lipid replacements that are designed to bind a broad range of oligonucleotide payloads, addressing another key safety concern with current LNP components. By engineering these critical LNP ingredients from the ground up using its proprietary POZ technology, Serina believes it can improve both the safety and versatility of LNP-delivered therapeutics.
- Serina Therapeutics will present at the 5th LNP Formulation & Process Development Summit on April 7, 2026.
The players
Serina Therapeutics
A clinical-stage biotechnology company developing a pipeline of drug candidates using its proprietary POZ Platform technology.
Randall Moreadith, MD, PhD
Chief Development Officer at Serina Therapeutics, who will be presenting the company's novel lipid nanoparticle technology at the summit.
What they’re saying
“Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma”
— Randall Moreadith, MD, PhD, Chief Development Officer, Serina Therapeutics
“Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads”
— Randall Moreadith, MD, PhD, Chief Development Officer, Serina Therapeutics
What’s next
Serina plans to continue advancing its POZ-based lipid nanoparticle technology through further research and development, with the goal of unlocking the full potential of this important drug delivery platform.
The takeaway
Serina Therapeutics' innovative POZ Platform technology aims to address key safety and versatility limitations of current lipid nanoparticle formulations, which could have significant implications for the future of oligonucleotide-based therapeutics and vaccines.
